

th


International Meeting on Lung Cancer

Hybrid Event

September
13-15 2023

Domotel Kastri Hotel
154 El. Venizelou Str., Kastri, Kifissia

Organized by



Under the auspices of



HELLENIC
SOCIETY OF
MEDICAL
ONCOLOGY



Hellenic
Society of
Pathology


Secretariat



Scientific | Cultural Events & Publications

www.scep.gr





Welcome Letter

Dear Colleagues,

Dear Friends,

We reached the 4th year of our initiative to create a scientific network among the doctors and scientists involved in the research and management of lung cancer. This year will be the first time that the "4th International Meeting on Lung Cancer" will be realized under "normal conditions" and without the restrictions related to the Covid-19 pandemic allowing us to focus on our original vision of scientific networking among scientists who have focused their activities on Thoracic Oncology. Therefore, in order to promote our goal which is to achieve a closer contact between the scientific community in Greece and abroad in the field of Thoracic Oncology, we considered that it would be very important and helpful to structure a "less strict and more free" scientific program prioritizing discussions and exchange of ideas, helping to develop partnerships between those who are interested. In this effort, we also believe that the participation of the pharmaceutical industry would be important and welcome. Finally, we also believe that this networking could be the basis of promoting the next generation of cancer researchers' training.

We would like to welcome all the participants in the "4th International Meeting on Lung Cancer" expressing our thanks for your support.

The Organizing & Scientific Committee

P. Christopoulos

Professor of Medicine at Heidelberg University, MD, PhD,
Hematologist & Medical Oncologist in
the Thoraxklinik and National Center for Tumor Diseases
(NCT) at Heidelberg University Hospital, Germany

F. Koinis

MD, PhD, Assistant Professor of
Medical Oncology, Faculty of Medicine,
School of Health Sciences,
University of Thessaly, Larissa, Greece

F.I. Dimitrakopoulos

MD, PhD, Medical Oncologist, Division of Oncology &
Molecular Oncology Laboratory, Department of Medicine,
University of Patras, Greece

D. Papadatos - Pastos

MRCP(UK) PhD, Consultant in Medical Oncology,
Lung Cancer and Acute Oncology,
University College London Hospitals and
The Princess Alexandra Hospital, UK



Wednesday, 13 September 2023

12.30-13.00 **Registration - Welcome address**

13.00-14.00 **Lectures**

Chairs: **V. Georgoulas (GR), F.I. Dimitrakopoulos (GR)**

13.00-13.20 Advancing the Lung Cancer Treatment Landscape	Ch. Fokoloros (GR)
13.20-13.40 Improving IO outcomes in NSCLC – The GSK R&D strategy	V. Chantzara (GR)
13.40-14.00 Thoracic SMARCA4-undifferentiated tumor: What we know so far	K. Linos (US)

14.00-15.20 **Oral Presentations (ongoing research)**

Chairs: **A. Kotsakis (GR), K. Baxevanis (GR)**

14.00-14.10 Conceptualisation of the antigen presenting cell landscape in lung cancer	M. Tsoumakidou (GR)
14.10-14.20 Immune landscape in periphery of non-small cell lung cancer patients	P. Verginis (GR)
14.20-14.30 Predictive biomarkers for immunotherapy response	A. Kotsakis / A. Xagara (GR)
14.30-14.40 Characterization of the inflammatory infiltrate in non-small cell lung carcinoma	I. Pateras (GR)
14.40-14.50 Unveiling the complexity of immune microenvironment in lung cancer	A. Giatromanolaki (GR)
14.50-15.00 Clinical value of NF-κB transcription factor in NSCLC patients	F.I. Dimitrakopoulos (GR)
15.00-15.10 Clinical and experimental research in lung cancer immuno-RT	M. Koukourakis (GR)
15.10-15.20 Reverse translational exploration of the TME in oncogene-driven NSCLC	P. Christopoulos (DE)

15.20-16.10 **Light Lunch**

16.10-18.00 **Networking Discussion & Exchange**

Fostering Greek Lung Cancer Research Networking

Chairs: **P. Christopoulos (DE), D. Papadatos-Pastos (UK), A. Kotsakis (GR), Ph. Koinis (GR), F.I. Dimitrakopoulos (GR)**

18.00-18.40 **SESSION: Oncogene-driven Lung Cancer**

Chairs: **N. Karachaliou (DE), Ph. Koinis (GR)**

18.00-18.20 Update on targeted perioperative therapies	P. Economopoulou (GR)
18.20-18.40 Metastatic NSCLC with actionable genetic alterations	G. Fotopoulos (CY)

18.40-19.10 **Invited Lectures**

Chairs: **F. I. Dimitrakopoulos (GR), G. Tsakonas (SWE)**

18.40-19.10 The future of KRAS targeting	A. Koulouris (SWE)
19.10-19.40 Translational Genomics for Precision Oncology: Focus on Liquid Biopsies	V. Anagnostou (US)

19.40 **Exchange**

KEYTRUDA® (pembrolizumab) for Infusion 100mg

Για την πλήρη περιήληψη των χαρακτηριστικών του προϊόντος, παρακαλούμε να απευθύνεστε στην MSD ΑΦΒΕΕ, Αγίου Δημητρίου 63, 174 56, Άλιμος. Τηλ.: 210 9897 300, Αρ. ΓΕΜΗ 121808101000

KEYTRUDA C/S.SOL.IN 25MG/ML BTx1 VIALx4ML : 2.593,93 € (X.T) 2.818,31 € (Λ.T) 2.332,24 € (N.T.)



σηθήστε να γίνουν τα φάρμακα πιο ασφαλή και **Αναφέρετε ΟΛΕΣ** τις ανεπιθύμητες ενέργειες για **ΟΛΑ** τα φάρμακα Συμπληρώνοντας την «**ΚΙΤΡΙΝΗ ΚΑΡΤΑ**»

GR-KEY-00675-20/02/2023



4th International Meeting on Lung Cancer September **13-15** 2023

Thursday, 14 September 2023

08.30-09.20 **SESSION: Stage I-III Lung Cancer**

Chairs: **G. Fotopoulos (CY), N. Panagiotopoulos (UK)**

08.30-08.50 The emerging relevance of peri-operative immunotherapy in NSCLC

P. Savvides (US)

08.50-09.10 Unresectable locally advanced NSCLC

Ph.Koinis (GR)

09.10-09.20 Discussion

09.20-10.10 **SESSION: IO - metastatic Lung cancer**

Chairs: **A. Dimou (US), A. Georgiou (UK)**

09.20-09.40 Frontline Immunotherapy for advanced NSCLC

D. Papadatos-Pastos (UK)

09.40-10.00 Therapeutic options after immunotherapy failure

Ch. Charalambous (CY)

10.00-10.10 Discussion

10.10-10.30 **Coffee Break**

10.30-11.30 **SESSION: TRACERx team**

Chairs: **D. Papadatos-Pastos (UK), A. Voutsina (GR)**

10.30-11.00 The evolution of non-small cell lung cancer metastases

M. Al Bakir (UK)

11.00-11.30 Evolutionary characterisation of lung adenocarcinoma morphology

D. Moore (UK)

11.30-12.30 **Lectures**

Chairs: **A. Kotsakis (GR), P. Savvides (US)**

11.30-12.00 Advancements in the field of ALK+NSCLC treatment

D. Thomaidou (GR)

12.00-12.30 Emerging treatment approaches for NSCLC

A. Nikolaou (GR)

12.30-14.00 **Light Lunch**

14.00-15.40 **Oral Presentations - Exchange (molecular targets / profiling / Biomarkers)**

Chairs: **F.I. Dimitrakopoulos (GR), V. Anagnostou (US)**

14.00-14.10 Validation of the ALK-Brain Prognostic Index (ALK-BPI) for patients with ALK-rearranged lung cancer and brain metastases

G. Tsakonas (SWE)

14.10-14.20 Stockholm Gamma Knife brain prognostic index (SGK-BPI) for lung cancer patients with brain metastases eligible for stereotactic CNS radiotherapy

G. Tsakonas (SWE)

14.20-14.30 Effectiveness of immunotherapy in Large Cell Neuroendocrine Carcinoma

G. Evangelou (GR)

14.30-14.40 Liquid biopsy: development of assays for the molecular characterization of CTCs and cfDNA

A. Markou (GR)

14.40-14.50 Novel Biomarkers on CTCs and EVs from Non-Small and Small Cell Lung Cancer Patients

G. Kallergi (GR)

14.50-15.00 Rare molecular targets in NSCLC and the significance of Real World Evidence

I. Mountzios (GR)

15.00-15.10 NGS-based ctDNA analysis in NSCLC: Challenges and Opportunities

A. Voutsina (GR)



4th International Meeting on Lung Cancer September 13-15 2023

- 15.10-15.20 Therapeutic implications of homologous recombination deficiency in non-small cell lung cancer **K. Tsilingiri (GR)**
15.20-15.30 Digital Therapeutics: quality of life support for cancer patients **Th. Kosmidis (GR)**
15.30-15.40 Studies with multiple pillars: the example of the CLIMEDIN study **H. Linardou (GR)**

15.40-16.40 Exchange

Chairs: **D. Papadatos-Pastos (GR), N. Karachaliou (DE), Ph. Koinis (GR), F. I. Dimitrakopoulos (GR), P. Christopoulos (GR)**

16.40-17.00 Coffee Break

17.00-18.20 SESSION: Emerging therapeutic options in NSCLC

Chairs: **I. Boukovinas (GR), V. Georgoulas (GR)**

- 17.00-17.20 PARP inhibition in Lung Cancer **A. Klinakis (GR)**
17.20-17.40 PARP inhibition combined with immunotherapy **S. Linardopoulos (UK)**
17.40-18.00 T-cell therapy in Lung Cancer **V. Tseveleki (GR)**
18.00-18.20 The future of specific antibodies and ADCs in NSCLC **N. Karachaliou (DE)**

18.20-19.00 SESSION: Mayo Clinic Group (Tumor Board)

- 18.20-18.30 History; Structure and function **P. Savvides (US)**
18.30-18.45 Cases **A. Dimou (US)**
18.45-19.00 Incorporating Individualized Medicine patient information into patient treatment decisions **G. Vasmataz (US)**

19.00-20.00 Lectures

Chairs: **A. Kotsakis (GR), K. Linos (US)**

- 19.00-19.20 NF-κB and NSCLC **F.I. Dimitrakopoulos (GR)**
19.20-19.40 State of the art: Molecular diagnostic of NSCLC **A. Stenzinger (DE)**
19.40-20.00 The role of HLA genotype in lung cancer biology, diagnostics and therapeutics **A. Dimou (US)**

20.00 Exchange

From transformative medicines that take on the toughest challenges, to biosimilar and supportive care outcome-enabling solutions we're

ADVANCING ALL ANGLES OF CARE

AMGEN®

Oncology

GRC-980-0623-80001

Βεβαιώστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα
συμπληρώνοντας την "ΚΙΤΡΙΝΗ ΚΑΡΤΑ"

Αναφέρετε κάθε υποπληρωμένη ενέργεια σύμφωνα με το εθνικό σύστημα
αναφοράς στο Τμήμα Αναπληρωμένων Ενέργειων του Εθνικού Οργανισμού Φαρμάκων
(ΕΟΦ) Τηλ: 2132040300, Fax: 2106545555, με τη χρήση της Κίτρινης Κάρτας Αναφοράς
και στην ιστοσελίδα του ΕΟΦ: www.eof.gr για έντυπη ή ηλεκτρονική υποβολή ή
εναλλακτικά στην AMGEN Ελλάς Φαρμακευτικά Ε.Π.Ε. Τηλ: +30 2103447000.

Learn more at
AmgenOncology.com

AMGEN HELLAS ΕΠΕ
Αγ. Κωνσταντίνου 59-61
Green Plaza, κτίριο Γ, 15 124 Μαρούσι
Τηλ: 210 3447000 - Fax: 210 3447050
Email: info@amgen.gr, www.amgen.gr



Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Για πλήρεις συνταγογραφικές πληροφορίες συμβουλευτείτε την
Περίληψη Χαρακτηριστικών του Προϊόντος που διατίθεται από την εταιρεία.



PFIZER ΕΛΛΑΣ Α.Ε. Λ. Μεσογείων 243, Ν. Ψυχικό 15451, Αθήνα, Ελλάδα,
Τηλ. Επικοινωνίας 210-6785800, Αριθ. Γ.Ε.ΜΗ. 000242901000
PFIZER ΕΛΛΑΣ Α.Ε. (CYPRUS BRANCH) Λεωφόρος Αθαλάσσας 26, 2018 Λευκωσία,
Κύπρος, Τηλ. Επικοινωνίας: +357 22 817690



4th International Meeting on Lung Cancer September 13-15 2023

Friday, 15 September 2023

08.30-09.20 Lectures

Chairs: **M. Koukourakis (GR), P. Christopoulos (DE)**

08.30-08.50 Combine Radiotherapy with immunotherapy

08.50-09.10 Tumor microenvironment in NSCLC

09.10-09.20 Discussion

H. Gkika (DE)
A. Giatromanolaki (GR)

09.20-09.40 Coffee Break

09.40-10.50 SESSION: SCLC - Mesothelioma - Thymoma

Chairs: **D. Papadatos-Pastos (UK), A. Dimopoulos (GR)**

09.40-10.00 An update of the primary treatment of limited stage SCLC patients.

Is high dose twice daily radiotherapy better?

10.00-10.20 Updating the treatment of Malignant Mesothelioma

10.20-10.40 State-of-the-art treatment of thymic malignancies

10.40-10.50 Discussion

G. Tsakonas (SWE)
I. Metaxas (SUI)
S. Gennatas (UK)

10.50-11.10 Exchange / Sum Up

Νέα εποχή στην πρόληψη του καρκίνου του μαστού

BRCA1/2
&
PRS Polygenic
Risk
Score

Η συνδυαστική γονιδιακή ανάλυση
που μπορεί **να σώσει ζωές**
και **να προλάβει την εξέλιξη**
του καρκίνου του μαστού

577.133
γενετικές παραλλαγές
εξετάζονται στα PRS

Συστήνεται ιδιαίτερα για:

- Νεαρές γυναίκες με βεβαρημένο οικογενειακό ιστορικό καρκίνου του μαστού
- Συγγενείς πρώτου βαθμού ασθενών με καρκίνο μαστού, που νόσησαν σε νεαρότερη ηλικία, κάτω των 45 ετών



prevention.bioiatriki.gr



4th International Meeting on Lung Cancer September 13-15 2023

FACULTY

Al Bakir M. Clinical Lecturer in Medical Oncology, UCLH and UCL Cancer Institute, Clinical Research Fellow, Francis Crick Institute, London, UK

Anagnostou V. MD, PhD, Associate Professor, Medical Oncology, Director, Thoracic Oncology Biorepository, Co-director, Thoracic Oncology Precision Medicine Center of Excellence, Upper Aerodigestive Oncology Program, Co-leader, Molecular Tumor Board, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, USA

Boukovinas I. MD, PhD, PharmaD, Medical Oncologist, Head of Oncology Unit, Bioclinic Thessaloniki, Greece

Baxevanis C. Scientific Director, Cancer Immunology and Immunotherapy Center, St. Savvas Cancer Hospital, Athens, Greece

Charalambous C. BM, MRCP, FRCR, Consultant Clinical Oncologist, Bank of Cyprus Oncology Centre, Nicosia, Cyprus

Chantzara V. Medical Science Liaison Oncology, GSK

Christopoulos P. Professor of Medicine, Heidelberg University, MD, PhD, Hematologist & Medical Oncologist at Heidelberg University Hospital, Germany

Dimitrakopoulos F.I. MD, PhD, Medical Oncologist, Division of Oncology & Molecular Oncology Laboratory, Department of Medicine, University of Patras, Greece

Dimou A. MD, Senior Associate Consultant, Division of Medical Oncology, Assistant Professor of Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA

Dimopoulos A. MD, PhD, Director of Radiation Oncology Department, Metropolitan Hospital Medical University of Vienna, Estro Faculty Member

Economopoulou P. MD, PhD, Consultant Medical Oncologist, 2nd Department of Internal Medicine, Attikon University Hospital, Greece

Evangelou G. Medical Oncologist, MB, MSc, 3rd Department of Medicine, Sotiria Hospital, Athens, Greece

Fokoloros Ch. MD PhDc, Medical Advisor - Oncology Pipeline Medical Lead, Amgen Hellas

Fotopoulos G. MD, FSMB (USA), PhD, Bank of Cyprus Oncology Center, Medical Oncology Consultant, UT Health San Antonio MD Anderson Alumni

Gennatas S. BSc, MBChB, MRCP(UK), PhD, Consultant Medical Oncologist with a Specialist Interest in Thoracic Cancers and Acute Oncology, Guy's and St Thomas' NHS Foundation Trust, UK

Georgiou A. MBChB, PhD, BSc, MRCP, Consultant Medical Oncologist Guy's and St. Thomas's and Kings College Hospitals, Honorary Senior Lecturer King's College London, UK

Georgoulas V. Emeritus Professor of Medical Oncology, School of Medicine, University of Crete, Greece

Giatromanolaki A. Professor of Pathology, Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece

Gkika H. Professor, Vice Chair of the Department of Radiation Oncology and Head of the section translational radiation oncology, University Medical Center Freiburg, Germany

Kallergi G. Assistant Professor of Biochemistry, Department of Biology, University of Patras, Greece



Πριν τη συνταγογράφηση συμβουλευθείτε την Περίληψη Χαρακτηριστικών των Προϊόντων η οποία είναι διαθέσιμη κατόπιν αιτήσεως στην εταιρεία.
Zejula: Α.Τ. 4.267,63 €, % επιχορήγησης από τους οργανισμούς κοινωνικών ασφαλίσεων: 100%, κατόπιν ένταξης του προϊόντος στον Κατάλογο Αποζημιούμενων Φαρμάκων. Περιορισμένη ιατρική συνταγή. Η ένταξη της θεραπείας γίνεται σε νοσοκομείο και μπορεί να συνεχίζεται εκτός νοσοκομείου υπό την παρακολούθηση ειδικού ιατρού.

Ποιοτική και ποσοτική σύνθεση: Το κάθε σκληρό καψάκιο περιέχει μονοϋδρική τοσυλική νιραπαρίμπη που ισοδυναμεί προς 100 mg νιραπαρίμπη.

Jemperli: Α.Τ. 6.463,80 €, % επιχορήγησης από τους οργανισμούς κοινωνικών ασφαλίσεων: 100%, κατόπιν ένταξης του προϊόντος στον Κατάλογο Αποζημιούμενων Φαρμάκων. Μόνο για νοσοκομειακή χρήση από γιατρό με κατάλληλη ειδίκευση και εμπειρία.

Ποιοτική και ποσοτική σύνθεση: Ένα φιαλίδιο πυκνού διαλύματος για παρασκευή διαλύματος προς έγχυση των 10 ml περιέχει 500 mg dostarlimab.

▼ Το φάρμακο αυτό τελεί υπό συμπληρωματική παρακολούθηση. Αυτό θα επιτρέψει το γρήγορο προσδιορισμό νέων πληροφοριών ασφάλειας. Ζητείται από τους επαγγελματίες υγείας να αναφέρουν οποιεσδήποτε πιθανολογούμενες ανεπιθύμητες ενέργειες. Βλ. παράγραφο 4.8 για τον τρόπο αναφοράς ανεπιθύμητων ενεργειών.

Τα ανωτέρω ισχύουν κατά την ημερομηνία σύνταξης της καταχώρησης.

Παρακαλούμε επικοινωνήστε με την εταιρεία για επιβεβαίωση πλήρους ενημερωμένων δεδομένων, για οποιαδήποτε πληροφορία ή/και αναφορά Ανεπιθύμητων Ενεργειών στο τηλέφωνο 210 6882100.

Τα εμπορικά σήματα ανήκουν ή έχουν παραχωρηθεί στον Όμιλο εταιρειών GSK.
©2023 Όμιλος εταιρειών GSK ή δικαιούχος του Ομίλου GSK.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

GlaxoSmithKline ΜΟΝΟΠΡΟΣΩΠΗ Α.Ε.Β.Ε
Λ. Κηφισίας 266, 15232 Αθήνα, Τηλ. 210 6882100
www.gr.gsk.com



4th International Meeting on Lung Cancer September 13-15 2023

Karachaliou N. MD, PhD, Medical Director, Global Clinical Development, Merck KGaA, Darmstadt, German

Klinakis A. PhD, Investigator, Biomedical Research Foundation of the Academy of Athens, Greece

Koinis F. MD, PhD, Assistant Professor of Medical Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece

Kosmidis Th. Co-founder & CEO at Care Across. Past Assembly member of the European Commission "Mission on Cancer", Expert In Residence at Imperial Enterprise Lab.

Kotsakis A. MD, PhD, Associate Professor of Medical Oncology, Director of Department of Medical Oncology, University Hospital of Larissa, Thessaly, Greece

Koulouris A. MD, Oncologist, Theme Cancer, Karolinska University Hospital, Department of Oncology-Pathology, Karolinska Institutet, Sweden

Koukourakis M. Professor of Radiotherapy and Oncology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece

Linardopoulos S. Director, Translational Science, Oncology AstraZeneca, Cambridge, UK

Linou K. MD, FASDP, Associate Attending, Department of Pathology, Memorial Sloan Kettering Cancer Center, NY, USA

Linardou H. Medical Oncologist, Board Member of FairLife LCC, Director, 4th Oncology Department Metropolitan Hospital, President of the Scientific Committee HeCOG, Athens, Greece

Markou A. PhD, Assistant Professor, Lab of Analytical Chemistry, Department of Chemistry, University of Athens, Greece

Metaxas I. MD, Senior Consultant Medical Oncology, Cantonal Hospital Muensterlingen, Switzerland

Moore D. CRUK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK

Mountzios I. MD, MSc, PhD, Medical Oncologist, Director, 4th Oncology Department and Clinical Trials Unit, Henry Dunant Hospital Center, ONCOLIFE Network Founder, Athens, Greece

Nikolaou A. MD, MSc, Medical Manager Oncology, Lung / Head & Neck, Astra Zeneca

Panagiotopoulos N. Consultant Thoracic and Robotic Surgeon, Cleveland Clinic London, UK

Papadatos-Pastos D. MRCP(UK) PhD, Consultant in Medical Oncology, Lung Cancer and Acute Oncology, University College London Hospitals and The Princess Alexandra Hospital, UK


Pateras I. Pathologist, Assistant Professor, 2nd Department of Pathology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, Greece

Savvides P. MD, PhD, MPH, Senior Associate Consultant, Thoracic H&N Medical Oncology, Mayo Clinic Arizona, USA

Stenzinger A. Institute of Pathology, University Hospital Heidelberg, Germany

Thomaidou D. Senior Director, Global Medical Affairs, Precision Medicine, Lung Cancer, Pfizer

Tsakonas G. MD, PhD, Senior Consultant in Oncology, Senior Researcher, Lung Oncology Center, Theme Cancer Oncology and Pathology Department, Karolinska University Hospital, Karolinska Institutet, Solna, Sweden



4th International Meeting on Lung Cancer September 13-15 2023

Tseveleki V. PhD, Chief Operating Officer, Theracell Laboratories

Tsiligiri K. PhD, Cancer Biology Laboratory, Center of Basic Research, Biomedical Research Foundation of the Academy of Athens, Greece

Tsoumakidou M. MD, PhD, Group Leader, Institute of Bioinnovation, BSRC Alexander Fleming, Athens, Greece

Verginis P. Associate Professor, Immunology/Biochemistry, Laboratory of Immune Regulation and Tolerance, Medical School, University of Crete, Heraklion, Greece

Voutsina A. Biologist MSc, PhD HORG, Athens

Xagara A. PhD, Molecular Biologist, Postdoctoral Researcher, Department of Medical Oncology, University General Hospital of Larissa, Greece



4th International Meeting on Lung Cancer September 13-15 2023

INFO

Organized by  Παγκρήτια Ένωση
Βιοϊατρικής Έρευνας
Cretan Association
For Biomedical Research

Under the auspices of   

Date

September 13-15, 2023

Place

The Hybrid Event will take place at Domotel Kastri Hotel (154, El. Venizelou Str., Kastri, Kifissia)

Registration

Free


You can watch the Hybrid Event online through the Link www.livetime.gr and ask written questions throughout the presentations

The Symposium will be accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with CME credits (ECMEC®s)

Certificate of Attendance

The certificate of attendance will be given to the participants at the end of the event. Based on the latest circular of the National Drug Organization the Event is required to use an attendance tracking system. By the end of the event a certificate will be given to those who have attended at least 60% of the total hours of the scientific Program. The number of credits of Continuing Medical Education (CME-CPD) to be administered to the participants will be calculated on the basis of monitoring time.


Secretariat



Scientific | Cultural Events & Publications

T +30 210 7240039 E info@scep.gr

www.scep.gr



Sponsors




AENORASIS
Intuition in Healthcare

AMGEN[®]
Oncology

AstraZeneca



Βιοιατρική
ΟΜΙΛΟΣ ΕΤΑΙΡΕΙΩΝ ΥΓΕΙΑΣ

 **Bristol Myers Squibb**[™]

 **GENESIS**
pharma



Sponsors

GSK

 **MSD**
INVENTING FOR LIFE

 **OPUS MATERIA**
ΕΠΙΣΤΗΜΟΝΙΚΑ ΟΡΓΑΝΑ - ΦΑΡΜΑΚΕΥΤΙΚΑ ΠΡΟΪΟΝΤΑ

 **Pfizer**
Oncology


Pierre Fabre
FARMAKA S.A.

 **WinMedica**
Serving Health for Life



